Engineers Gate Manager’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$543K Buy
18,790
+75
+0.4% +$2.02K 0.01% 1452
2026
Q1
$339K Sell
18,715
-87,425
-82% -$1.67M ﹤0.01% 1645
2025
Q4
$2.31M Buy
106,140
+64,237
+153% +$1.84M 0.03% 639
2025
Q3
$1.37M Buy
41,903
+31,182
+291% +$1.15M 0.02% 986
2025
Q2
$380K Sell
10,721
-51,763
-83% -$1.68M ﹤0.01% 1609
2025
Q1
$2.12M Sell
62,484
-4,132
-6% -$148K 0.04% 669
2024
Q4
$2.17M Buy
66,616
+54,862
+467% +$2.27M 0.04% 591
2024
Q3
$573K Sell
11,754
-5,160
-31% -$275K 0.01% 1312
2024
Q2
$749K Sell
16,914
-5,877
-26% -$271K 0.02% 1044
2024
Q1
$1.28M Sell
22,791
-10,373
-31% -$626K 0.03% 691
2023
Q4
$2M Buy
33,164
+29,378
+776% +$1.86M 0.06% 478
2023
Q3
$254K Sell
3,786
-3,404
-47% -$236K 0.01% 1398
2023
Q2
$496K Buy
+7,190
New +$470K 0.02% 1039

Other funds holding LEGN

Engineers Gate Manager's LEGN Position: Q2 2026 in Review

Engineers Gate Manager increased its Legend Biotech (LEGN) stake by 0.4% in Q2 2026, buying an estimated $2.02K and bringing the position to 18,790 shares worth $543K. The position accounts for 0.01% of the portfolio, ranked #1452.

Engineers Gate Manager first reported a position in LEGN in Q2 2023 and has held it in 13 quarters since. The position peaked at $2.31M in Q4 2025. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Engineers Gate Manager held 18,790 shares of Legend Biotech worth $543K as of Q2 2026.
  • Engineers Gate Manager bought 75 Legend Biotech shares in Q2 2026, an estimated $2.02K.
  • Legend Biotech made up 0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1452 holding.
  • Engineers Gate Manager first reported a position in Legend Biotech in Q2 2023 and has held it in 13 quarters since.
  • Engineers Gate Manager's Legend Biotech position peaked at $2.31M in Q4 2025.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.